Assessment of prophylactic antibiotics administration for acute pancreatitis: a meta-analysis of randomized controlled trials

Nan Ding¹, Yong-Hui Sun², Li-Mei Wen¹, Jian-Hua Wang¹, Jian-Hua Yang¹, Kun Cheng², Hai Lin², Qi-Long Chen²

¹Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China;
²Digestion and Vascular Center, Department of Pancreas Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054, China.

Abstract

Background: Recent evidence has shown that prophylactic antibiotic treatment in patients with acute pancreatitis is not associated with a significant decrease in mortality or morbidity. The use and efficacy of prophylactic antibiotic treatment in acute pancreatitis remain controversial. This meta-analysis was conducted to assess whether antibiotic prophylaxis is beneficial in patients with acute pancreatitis.

Methods: We searched randomized controlled trials (RCTs) of prophylactic use of antibiotics using Medline (PubMed), Embase, the Cochrane Library, and Web of Science. The data were analyzed using Review Manager 5.3 software. We performed pooled analyses for infected pancreatic necrosis, mortality, surgical intervention, and non-pancreatic infection. Odds ratios (ORs) from each trial were pooled using a random or fixed effects model, depending on the heterogeneity of the included studies. Sub-group analysis or sensitivity analysis was conducted to explore potential sources of heterogeneity, when necessary.

Results: Totally, 11 RCTs involving 747 participants were included, with an intervention group (prophylactic use of antibiotics, n = 376) and control group (n = 371). No significant differences were found regarding antibiotic prophylaxis with respect to incidence of infected pancreatic necrosis (OR, 0.74; 95% confidence interval [CI], 0.50–1.09; P = 0.13), surgical intervention (OR, 0.92; 95% CI, 0.62–1.38; P = 0.70), and mortality (OR, 0.71; 95% CI, 0.44–1.15; P = 0.16). However, antibiotic prophylaxis was associated with a statistically significant reduction in the incidence of non-pancreatic infection (OR, 0.59; 95% CI, 0.42–0.84; P = 0.004).

Conclusions: Prophylactic antibiotics can reduce the incidence of non-pancreatic infection in patients with AP.

Keywords: Acute pancreatitis; Prophylactic administration; Antibiotics; Meta-analysis

Introduction

Acute pancreatitis (AP) is one of the most common gastrointestinal diseases. AP is an inflammatory condition of the pancreas, mostly caused by gallstones or excessive alcohol consumption.¹ AP is classified as mild, moderate, or severe based on the 2012 revised Atlanta classification definition.² Mild AP (MAP) is a self-limiting disease, with recovery usually occurring in the first week. The primary treatment for MAP is supportive care, including fluid resuscitation and pain control. The mortality rate of AP is roughly 5%; this rate is higher for severe AP (SAP). SAP is usually associated with a systemic inflammatory response, infection of the pancreas and peripancreatic necrosis, single or multiple organ failure, and even death.³⁻⁵

About 20% to 40% of patients with SAP develop infection of the pancreas and peripancreatic necrosis, with infected necrosis representing the primary cause of death. It is unclear whether prophylactic antibiotics are beneficial in AP to prevent infected necrosis and reduce the incidence of death. Several studies have demonstrated that prophylactic antibiotic treatment may reduce the incidence rate of infected pancreatic necrosis.⁶⁻⁷ However, other studies have shown that the use of antibiotic prophylaxis is not associated with the incidence of pancreatic infection and death.⁸⁻⁹ In addition, several clinical guidelines suggest that prophylactic antibiotics are not recommended.⁴⁰⁻¹² Although several clinical trials and guidelines point out that prophylactic antibiotics are not beneficial in preventing infected necrosis and reducing the incidence of complications and death, some physicians still choose to administer prophylactic antibiotics to patients with AP.
Clearly, the use and efficacy of prophylactic antibiotic treatment in AP remain a point of controversy. Moreover, there is no conclusive evidence available in this regard among published meta-analyses and reviews.[13-15] Thus, we conducted the present meta-analysis to assess whether antibiotic prophylaxis is beneficial in AP. In this meta-analysis, we focused not only on mortality and morbidity but also on specific infections such as pneumonia, urinary tract infection (UTI), positive blood culture, and fungal infection.

Methods

Systematic literature search

A systematic literature search was conducted independently by two authors using methods of the Cochrane Collaboration. We systematically searched MEDLINE (PubMed), Embase, the Cochrane Library, and Web of Science. We performed a literature search for randomized controlled trials (RCTs) published from inception to June 2019 evaluating the prophylactic use of antibiotics in patients with AP or SAP. Databases were queried for eligible studies using combinations of the following keywords: “acute pancreatitis,” “severe acute pancreatitis,” “prophylactic use of antibiotics,” “antibiotic prophylaxis,” “antibiotics,” and “prophylaxis.” We reviewed the titles and abstracts of possibly relevant studies. Full-text articles were obtained for comprehensive evaluation, and eligible studies were included in our meta-analysis.

Eligibility criteria

Peer-reviewed reports of studies that met the following criteria were eligible for inclusion: (1) the aims of the trial were to assess prophylactic use of antibiotics; (2) written in any language; (3) study population comprised patients with AP or SAP or acute necrotizing pancreatitis; (4) the name and dose of antibiotics were described; and (5) RCTs.

Outcome measures

The following parameters were extracted using standardized forms: (1) primary outcome parameters: the incidence of infected pancreatic necrosis and mortality; (2) secondary outcome parameters: the incidence of surgical intervention, non-pancreatic infection, pneumonia, UTI, positive blood culture, and fungal infection.

Quality assessment

The quality of 11 RCTs was assessed using Cochrane Collaboration Review Manager 5.3 software (Cochrane Collaboration, Oxford, UK). The risk of bias among RCTs was evaluated with the Cochrane Collaboration’s Risk of Bias Tool. Items were judged as “low risk,” “unclear risk,” or “high risk”; red indicates “high risk,” green “low risk,” and yellow “unclear risk.” Seven parameters were used to estimate the quality of each included study: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other risks.

Data extraction

Data were extracted independently by two authors. The extracted data included first author, year of publication, the number of patients allocated to each group, name, and dose of antibiotics, time of antibiotics administration, duration of antibiotics prophylaxis, and the outcome variables listed above. Disagreement between investigators was discussed and resolved by consensus.

Statistical analysis

This meta-analysis was carried out using Cochrane Collaboration Review Manager 5.3 software; outcomes are presented as forest plots. The vertical line represents the line of equivalence between the groups being compared. The squares for each trial represent the point estimate, with the area of the square being proportional to the sample size; the line represents the 95% confidence interval (CI). Summary measures are depicted using diamonds, where the width of the diamond represents the 95% CI. Statistical analysis was conducted using the Mantel-Haenszel method, and summary statistics are presented as odds ratios (ORs). An OR of less than 1 favors the intervention group, and the point estimate of the OR was considered statistically significant at the P<0.05 level if the 95% CI did not include value 1. A fixed effects model was adapted for all outcome measures. We calculated the I² value to estimate homogeneity. When the I² value was greater than 50%, a random effects model was adopted.

Results

Description of eligible studies

In this comprehensive literature review, we initially searched 817 potential titles and abstracts, after selection, 11 RCTs finally met the inclusion criteria.[6-9,16-22] A detailed search flow diagram is shown in Figure 1. After reading the full text of the remaining articles, 11 articles were selected. The characteristics of RCTs included in the meta-analysis are shown in Table 1. Summarized results of the risk of bias assessment are shown in Figure 2.
A total of 747 patients were included in the 11 articles with results regarding infected pancreatic necrosis [Figure 3]. Totally, 63 of 376 patients (16.8%) in the antibiotic prophylaxis group developed infected necrosis whereas 76 of 371 (20.5%) in the control group developed infected necrosis. The overall OR was 0.74 (95% CI, 0.50–0.98), demonstrating no statistical significance.

**Meta-analysis of infected pancreatic necrosis**

A total of 747 patients were included in the 11 articles with results regarding infected pancreatic necrosis [Figure 3]. Totally, 63 of 376 patients (16.8%) in the antibiotic prophylaxis group developed infected necrosis whereas 76 of 371 (20.5%) in the control group developed infected necrosis. The overall OR was 0.74 (95% CI, 0.50–0.98), demonstrating no statistical significance.

**Meta-analysis of mortality**

Totally, 32 of 327 (9.8%) patients in the intervention group and 43 of 322 (13.4%) patients in the control group died [Figure 4]. The overall OR was 0.71 (95% CI, 0.44–1.15; P = 0.16; I² = 0), indicating that antibiotics were not associated with significantly reduced mortality.

**Meta-analysis of surgical intervention**

A total of 576 patients were included in eight studies comparing the use of prophylactic antibiotics with controls, with regard to surgical intervention [Figure 5]. Totally, 66 of 291 (22.7%) patients in the antibiotic prophylaxis group and 66 of 285 (23.2%) in the control group underwent surgery. The overall OR was 0.92 (95% CI, 0.62–1.38; P = 0.70; I² = 0). Antibiotics use was not associated with significantly reduced surgical intervention.

**Meta-analysis of non-pancreatic infection**

Among the included studies, non-pancreatic infections included pneumonia, UTI, positive blood culture, fungal infection, and others. Totally, 80 of 333 (24.0%) patients in the intervention group and 109 of 328 (33.2%) in the control group developed non-pancreatic infections [Figure 6]. The overall OR was 0.59 (95% CI, 0.42–0.84; P = 0.004), indicating that the use of antibiotics was associated with a significant reduction in the incidence of non-pancreatic infections. There was moderate heterogeneity among the trials (P = 0.06; I² = 47%). The Egger’s test for heterogeneity showed no publication bias (t = −0.04, P = 0.972) [Figure 7]. In the sensitivity analysis, after gradually eliminating each study, the outcome was found to be stable [Figure 8]. Sub-group analysis showed that there was no significant difference with respect to different study years [Figure 9A], sample size [Figure 9B], and antibiotics [Figure 9D]. However, a significant difference was found in single-center vs. multicenter sub-groups (single-center sub-group, five RCTs, 300 patients, OR: 0.86, 95% CI: 0.45–1.67; multicenter sub-group, OR: 0.40, 95% CI: 0.18–0.86) [Figure 9C].

**Meta-analysis of pneumonia**

Five included studies provided data on endocrine pneumonia [Figure 10], including 188 patients in the antibiotics group and 181 in the control group. Twenty-three of 188 (12.2%) patients in the antibiotics prophylaxis group developed pneumonia whereas 32 of 181 (17.7%) in the control group developed pneumonia (OR, 0.61; 95% CI, 0.32–1.14; P = 0.12; I² = 0).

**Meta-analysis of positive blood culture**

Fourteen of 130 (10.8%) patients in the antibiotics group had positive blood cultures whereas 20 of 125 (16.0%) in the control group had positive blood culture results (OR, 0.61; 95% CI, 0.29–1.30; P = 0.20; I² = 0) [Figure 11].

---

**Table 1: Characteristics of randomized controlled trials included in the meta-analysis.**

| First authors | Year | Study design | Clinical features | Number of patients (intervention/ control), n | Gender (male/ female) | Antibiotics and dosage | Time of administration (h) | Antibiotic duration (days) | Outcome measures |
|---------------|------|--------------|-------------------|---------------------------------------------|-----------------------|------------------------|--------------------------|---------------------------|------------------|
| Dellinger et al [1] | 2007 | RCT (multicenter) | Pancreatic necrosis on CT scan | 100 (50/50) | 70/30 | Meropenem (1 g, q8h) | <120 | 7–21 | 1, 2, 3, 4 |
| García-Barrasa et al [21] | 2009 | RCT (single-center) | Pancreatic necrosis on CT scan | 41 (22/19) | 29/12 | Ciprofloxacin (300 mg, q12h) | 48–72 | 10 | 1, 2, 3, 4 |
| Hemmann et al [31] | 2004 | RCT (multicenter) | Pancreatic necrosis on CT scan; CRP > 150 mg/L | 114 (58/56) | 87/27 | Ciprofloxacin (400 mg, q12h), meropenem (300 mg, q12h) | <72 | 14–21 | 1, 2, 3, 4 |
| Nordback et al [34] | 2001 | RCT (single-center) | Pancreatic necrosis on CT scan | 58 (25/33) | 51/7 | Imipenem (1 g, q8h) | <48 | Not stated | 1, 2, 3, 4 |
| Pedersen et al [15] | 1993 | RCT (multicenter) | Pancreatic necrosis on CT scan | 74 (41/33) | Not stated | Imipenem (0.5 g, q8h) | <72 | 14 | 1, 2, 3, 4 |
| Poropat et al [6] | 2016 | RCT (single-center) | Acute pancreatitis | 47 (23/24) | Not stated | Imipenem (0.5 g, q8h) | Not stated | 10 | 1, 2, 4 |
| Poropat et al [20] | 2017 | RCT (single-center) | Acute pancreatitis | 98 (49/49) | Not stated | Imipenem (0.5 g, q8h) | Not stated | 10 | 1, 2, 4 |
| Røkke et al [32] | 2007 | RCT (multicenter) | Pancreatic necrosis on CT scan; CRP > 120 mg/L; (24 h); CRP > 300 mg/L; (48 h) | 53 (36/37) | 49/24 | Imipenem (0.5 g, q8h) | <72 | 5–7 | 1, 2, 3, 4 |
| Sainio et al [7] | 1995 | RCT (single-center) | Low enhancement on CT scan; CRP > 120 mg/L | 60 (30/30) | 53/7 | Cefuroxime (1.5 g, q8h) | <48 | 14 | 1, 2, 3 |
| Schwarz et al [18] | 1995 | RCT (single-center) | Pancreatic necrosis on CT scan | 26 (13/13) | Not stated | Ofloxacin (300 mg, q12h), meropenem (300 mg, q12h) | Not stated | 10 | 1, 2 |
| Xue et al [9] | 2009 | RCT (single-center) | >30% pancreatic necrosis on CT scan | 56 (29/27) | 28/28 | Imipenem (0.5 g, q8h) | <72 | 7–10 | 1, 2, 3, 4 |

Meaning of numbers for outcome measures: 1: Death; 2: Infected pancreatic necrosis; 3: Surgical intervention; 4: Non-pancreatic infection; RCT: Randomized controlled trial; CT: Chemotherapy; CRP: C-reactive protein; APACHE II: Acute Physiology and Chronic Health Evaluation II.
Meta-analysis of fungal infection

Five of 177 (12.2%) patients in the antibiotics prophylaxis group developed fungal infection [Figure 12] compared with 5 of 168 (17.7%) patients in the control group (OR, 0.95; 95% CI, 0.30–3.03; \( P = 0.12; I^2 = 0 \)).

Meta-analysis of urinary tract infection

A total of 369 patients were included in five studies comparing prophylactic antibiotics use with controls with respect to UTI [Figure 13]; the incidence was 15 of 188 (25.0%) and 28 of 181 (33.9%) patients, respectively. Because the \( I^2 \) value was greater than 50%, the random effects model was adopted; the overall OR was 0.44 (95% CI: 0.22–0.89). Antibiotics use was associated with a statistically significant reduction in the incidence of UTI.

Discussion

Early clinical trials\(^6,7\) have shown that the use of antibiotic prophylaxis can obviously reduce the incidence rate of infected pancreatic necrosis. However, the 2015 Japanese guidelines for the management of AP suggest that prophylactic use of antibiotics in SAP and necrotizing pancreatitis could improve the prognosis if carried out in the early phase of pancreatitis (within 72 h of onset).\(^23\)

Moreover, the results of subsequent clinical studies differ with respect to a reduction in the mortality rate, surgical intervention, infected pancreatic necrosis, and non-pancreatic infection.\(^24,25\) García-Barrasa et al\(^9\) conducted an RCT to compare 22 patients who received intravenous ciprofloxacin with 19 who received placebo. Their findings suggested that the prophylactic use of ciprofloxacin did not significantly reduce the risk of developing pancreatic infection and did not decrease mortality. A recent study in Japan suggested that routine early prophylactic antibiotic use has no significant clinical benefit in patients with SAP but may increase the risk of hospital-acquired infections.\(^26\) Xue et al\(^21\) suggested that prophylactic use of antibiotics may increase the prevalence of multi-drug resistant bacteria and the incidence of fungal infection.
Owing to the different study designs, these studies showed conflicting and contradictory outcomes.

The results of several previously published meta-analyses have also differed. Most published meta-analyses have not focused on specific non-pancreatic infections such as pneumonia and UTI. Therefore, we conducted this meta-analysis to address this issue and included two newly published RCTs in the analysis. Our meta-analysis not only assessed the effects of the prophylactic use of antibiotics on mortality and infected pancreatic necrosis but also on pneumonia, UTI, and fungal infection, among others. In the present meta-analysis, we found that prophylactic use of antibiotics did not reduce the rate of...
mortality (OR = 0.71; 95% CI, 0.44–1.15; P = 0.16) [Figure 4], surgical intervention (OR = 0.92; 95% CI, 0.62–1.38; P = 0.70) [Figure 5], or infected pancreatic necrosis (OR = 0.74; 95% CI, 0.50–1.09; P = 0.13) [Figure 3]. However, the use of antibiotics was associated with a statistically significant reduction in the incidence of non-pancreatic infections (OR = 0.59; 95% CI, 0.42–0.84; P = 0.004) [Figure 6]. Non-pancreatic infections included pneumonia, UTI, positive blood culture, fungal infection, and others. Therefore, we further analyzed the effect of prophylactic use of antibiotics on pneumonia, UTI, positive blood culture, fungal infection. In this meta-analysis, we found that prophylactic use of antibiotics did not reduce the incidence of pneumonia (OR = 0.61; 95% CI, 0.32–1.14; P = 0.12) [Figure 10], positive blood culture (OR = 0.61; 95% CI, 0.29–1.30; P = 0.20) [Figure 11], or fungal infection (OR = 0.95; 95% CI, 0.30–3.03; P = 0.94) [Figure 12]. These results are mostly consistent with previous studies. However, antibiotic prophylaxis could reduce the incidence of UTI (OR = 0.44; 95% CI, 0.22–0.89; P = 0.02) [Figure 13].

Infected pancreatic necrosis is a leading cause of death in patients with AP. However, we found that antibiotic prophylaxis did not reduce the incidence rate of infected pancreatic necrosis and mortality. The prophylactic use of antibiotics may reduce the incidence of non-pancreatic infection according to our meta-analysis. We found that antibiotic prophylaxis only reduced the incidence of UTI. Sub-group and sensitivity analyses were implemented to investigate non-pancreatic infection owing to moderate heterogeneity. The Egger’s test indicated no publication bias and a stable outcome of sensitivity analysis. In the sub-group analysis, the results regarding non-pancreatic infection suggested that there were no differences in the before year of 2009 sub-group vs. year 2009 and later sub-group, <50 sub-group vs. 50 to 99 sub-group vs. ≥100 sub-group, and imipenem sub-group vs. other antibiotics sub-group. According to results for single-center vs. multicenter studies, patients treated with antibiotic prophylaxis had significantly less infection in the multicenter sub-group. A possible explanation may be that this finding is limited by the single-center’s medical level and regional differences.

According to the results of our meta-analysis, antibiotic prophylaxis did not reduce the incidence of infected pancreatic necrosis and surgical intervention. Mowery et al. suggested that demarcation of necrosis results in less injury to vital tissues with delayed surgery; there is less bleeding, and necrosectomy is more effective. The 2019
World Society of Emergency Surgery guidelines for the management of SAP suggests that postponing surgical interventions for more than 4 weeks after the onset of disease results in less mortality. Additional trials are needed to clarify whether antibiotic prophylaxis can delay surgical intervention in AP. In addition, a focus is required beyond only whether antibiotic prophylaxis is beneficial in AP. Greater attention is needed regarding the adverse effects of antibiotic prophylaxis in future studies, including increased prevalence of multi-drug resistant bacteria and incidence of fungal infection, among other effects. Fungal infection is a severe complication of AP related to an increase in morbidity and mortality. Thus, additional RCTs investigating the efficacy of antifungal prophylaxis in AP should be designed. Moreover, whether the results of antibiotic prophylaxis differ according to the etiology of pancreatitis is worth further exploration. The mechanism of infected pancreatic necrosis remains unclear. Some studies consider that transmission of organisms from the gastrointestinal tract to the pancreas is one cause. Thus, future trials should explore the cause of infected pancreatic necrosis.

There are several limitations in this meta-analysis. First, there is possible heterogeneity of the included articles. For instance, the different antibiotics, dosage, medical levels, timing of administration, antibiotic duration, and regional differences in each trial may have contributed to the heterogeneity. Second, the sample in some included articles was small. Third, there were differences with regard to pancreatitis etiology and severity of disease, among other factors. In the future, more high-quality RCTs are needed to yield a more persuasive meta-analysis.

In conclusion, the findings of our meta-analysis suggest that antibiotic prophylaxis may reduce the incidence of non-pancreatic infections in AP patients.
non-pancreatic infection and UTI in patients with AP. However, our results showed no differences in terms of infected pancreatic necrosis, mortality, surgical intervention, pneumonia, positive blood culture, and fungal infection. Therefore, the present study findings showed no statistically significant benefit of prophylactic antibiotic use in AP. Additional higher quality RCTs with larger sample sizes are needed to comprehensively assess the efficacy of antibiotic prophylaxis in patients with AP.

Conflicts of interest
None.

References
1. Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, et al. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include “moderately severe acute pancreatitis”. Am J Gastroenterol 2009;104:710–715. doi: 10.1038/aig.2008.77.
2. Banks PA, Bollen TL, Deravies C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102–111. doi: 10.1136/gutjnl-2012-302779.
3. Koutoumpakis E, Slivka A, Parlan A, Dasyam AK, Dudekula A, Greer JB, et al. Management and outcomes of acute pancreatitis patients over the last decade: a US tertiary-center experience. Pancreatology 2017;17:32-40. doi: 10.1016/j.pan.2016.10.011.
4. Sandzen B, Rosenmüller M, Haapamäki MM, Nilsson E, Stenlund HC, Oman M. First attack of acute pancreatitis in Sweden 1988-2003: incidence, aetiological classification, procedures and mortality - a register study. BMC Gastroenterol 2009;9:18. doi: 10.1186/1471-230X-9-18.
5. Jiang K, Huang W, Yang XN, Xia Q. Present and future of prophylactic antibiotics for severe acute pancreatitis. World J Gastroenterol 2012;18:279-284. doi: 10.3748/wjg.v18.i5.279.
6. Pederzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1995;176:480–483. doi: 10.1055/s-2007-1018835.
7. Sainio V, Kemppainen E, Paalzakken P, Taavitsainen M, Kiviisaari L, Valtonen V, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995;346:663–667. doi: 10.1016/s0140-6736 (95)92280-6.
8. Dellinger EP, Tellado JM, Soto NE, Ashley SW, Barie PS, Dugernier T, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg 2007;245:674–683. doi: 10.1097/01.sla.0000250414.09255.84.
9. García-Barraza A, Borobia FG, Pallares R, Jorba R, Poves I, Busquets J, et al. A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis. J Gastrointest Surg 2009;13:768–774. doi: 10.1007/s11605-008-0773-7.
10. Leppaniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg 2019;14:27. doi: 10.1186/s13017-019-0247-0.
11. Crockett SD, Wani S, Gardiner TB, Falc-Ytter Y, Barkun AN, American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology 2018;154:1096–1101. doi: 10.1053/j.gastro.2018.01.032.
12. Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg 2016;59:128–140. doi: 10.1503/cjs.013015.
13. Mazaki T, Ishii Y, Takayama T. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006;93:674–684. doi: 10.1002/bjs.5389.
14. Lim CL, Lee W, Liew YX, Tang SS, Chlebicki MP, Kwa AL. Role of antibiotic prophylaxis in necrotizing pancreatitis: a meta-analysis. J Gastrointest Surg 2015;19:480–491. doi: 10.1007/s11605-014-2662-6.
15. Ukai T, Shikata S, Inoue M, Noguchi Y, Igarashi H, Isaji S, et al. Early prophylactic antibiotics administration for acute necrotizing pancreatitis: a meta-analysis of randomized controlled trials. J Hepatobiliary Pancreat Sci 2015;22:316–321. doi: 10.1002/jhbp.221.
16. Schwarz M, Isenmann R, Meyer H, Beger HG. Antibiotic use in necrotizing pancreatitis. Results of a controlled study (in German). Dtsch Med Wochenschr 1997;122:356–361. doi: 10.1055/s-2008-1047621.
17. Poropat G, Giljaca V, Licul V, Hauser G, Milic S, Stmic D. Imipenem prophylaxis for predicted severe acute pancreatitis: preliminary results of a randomized clinical trial. Pancreatology 2016;16:589. doi: 10.1016/j.pan.2016.05.301.
18. Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis: a single-center randomized controlled study. J Gastrointest Surg 2001;5:113–118. doi: 10.1016/S1091-255X(01)00214-4.
19. Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004;126:997–1004. doi: 10.1053/gastro.2003.12.050.
20. Poropat G, Radovan A, Peric M, Mikolasevic I, Giljaca V, Hauser G, et al. Prevention of infectious complications in predicted severe acute pancreatitis (SAP): a single center randomized controlled trial. Pancreatology 2017;17:587. doi: 10.1016/j.pan.2017.05.274.
21. Xue P, Deng LH, Zhang ZD, Yang XN, Wan MH, Song B, et al. Effect of antibiotic prophylaxis on acute necrotizing pancreatitis: results of a randomized controlled trial. J Gastroenterol Hepatol 2009;24:736–742. doi: 10.1111/j.1440-1746.2008.05758.x.
22. Rokke O, Harbitz TB, Liljedal J, Pettersen T, Fetvedt T, Heen LO, et al. Early treatment of severe pancreatitis with imipenem: a prospective randomized clinical trial. Scand J Gastroenterol 2007;42:771–776. doi: 10.1080/00365520601173853.
23. Yokose M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, et al. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci 2015;22:403–432. doi: 10.1002/jhbp.239.
24. Sakorafas GH, Lappas C, Mastoraki A, Delis SG, Safiolaas M. Current trends in the management of infected necrotizing pancreatitis. Infect Disord Drug Targets 2010;10:9–14. doi: 10.2174/187152610790410936.
25. Villatoro E, Mulli M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2013;CD002941. doi: 10.1002/14651858.CD002941.pub3.
26. Nakahara K, Morita K, Jo T, Matsu H, Fushimi K, Yasunaga H. Early prophylactic antibiotics for severe acute pancreatitis: a population-based cohort study using a nationwide database in Japan. J Infect Chemother 2018;24:753–758. doi: 10.1016/j.jiac.2018.05.009.
27. Bai Y, Gao J, Zou DW, Li ZS. Prophylactic antibiotics cannot reduce infected pancreatic necrosis and mortality in acute necrotizing pancreatitis: evidence from a meta-analysis of randomized controlled trials. Am J Gastroenterol 2008;103:104–110. doi: 10.1111/j.1572-0241.2007.01575.x.
28. Mowery NT, Bruns BR, MacNew HG, Agarwal S, Ennuss TM, Khan M, et al. Surgical management of pancreatic necrosis: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2017;83:316–327. doi: 10.1097/TA.0000000000001510.
29. Schwender BJ, Gordon SR, Gardiner TB. Risk factors for the development of intra-abdominal fungal infections in acute pancreatitis. Pancreas 2015;44:805–807. doi: 10.1097/MPA.0000000000000334.

How to cite this article: Ding N, Sun YH, Wen LM, Wang JH, Yang JH, Cheng K, Lin H, Chen QL. Assessment of prophylactic antibiotics administration for acute pancreatitis: a meta-analysis of randomized controlled trials. Chin Med J 2020;133:212–220. doi: 10.1097/CM9.0000000000000603.